

Edgar Filing: ASTRALIS LTD - Form 8-K

results for the Phase II Study of Psoraxine for psoriasis. A copy of the press release is attached as Exhibit 99.1

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

This exhibit is furnished pursuant to Item 8.01 and shall not be deemed to be "filed".

Exhibit No.	Description
99.1	Press Release of Astralis Ltd., dated March 14, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASTRALIS LTD.

Date: March 14, 2005

By: /s/ James Sharpe

James Sharpe
Chief Executive Officer